We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GC Medical Science corp.

Download Mobile App




Centrifugal System Concentrates PRP from Blood

By HospiMedica International staff writers
Posted on 02 Mar 2020
An autologous biologic concentrating system allows the safe and rapid preparation of platelet rich plasma (PRP) from a small sample of blood at the point of care.

The EmCyte Corporation (Fort Myers, FL, USA) PurePRP Supraphysiologic Concentrating System is based a double spin centrifugal system designed to be used for the safe and rapid preparation of autologous PRP from a 30 to 120mL sample of the patient’s blood. More...
Following six and a half minutes of processing time, the system can deliver up to 95% platelet yield and nine-fold concentration into a 7-8 mL sample of PRP, without any red blood cell (RBC) content. The resulting supraphysiologic PRP is then aspirated from the container with a syringe.

The extracted PRP, which contains viable growth factors, non-inflammatory mediators, and cytokines, is then used on its own, or mixed with a blend of autograft and allograft bone prior to application to the designated surgical site in order to improve bone graft handling characteristics. The cell composition offers a powerful and viable boost to local tissue environment, making it an effective and well tolerated treatment application. Closed system processing and superior handling offer optimal sterility control and patient safety.

“Autologous regenerative medicine is fast becoming a standard of care and using the right biologic is vitally important to how patients respond. The PurePRP Supraphysiologic Concentrating System is the next step in clinical excellence,” said Patrick Pennie, President and CEO of EmCyte Corporation. “We believe we've hit the mark on this innovation after improving the clinical experience for both the practitioner and patient.”

PRP preparation involves the collection of the patient's whole blood which undergoes centrifugation to separate the PRP aliquot from platelet-poor plasma and RBCs, concentrating platelets in rich plasma by a three to nine-fold factor. PRP has been widely investigated and used as a clinical tool for several types of medical treatments, including nerve injury, tendinitis, osteoarthritis, bone repair and regeneration, and plastic and oral surgery.

Related Links:
EmCyte Corporation


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
New
Knee Arthroscopy Holder
Reison 10-353 XL
New
IV Therapy Cart
Avalo I.V Therapy Cart
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: New clinical guidance suggests treatments to prevent blood clots in CLTI patients after leg artery procedures (Photo courtesy of Shutterstock)

Stronger Blood Clot Prevention Measures Needed After Leg Artery Procedures in High-Risk Patients

Chronic limb-threatening ischemia (CLTI), the most severe form of peripheral artery disease (PAD), significantly reduces blood flow to the legs and feet. Despite undergoing lower limb revascularization... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: A research collaboration aims to further advance findings in human genomics research in cardiovascular diseases (Photo courtesy of 123RF)

Bayer and Broad Institute Extend Research Collaboration to Develop New Cardiovascular Therapies

A research collaboration will focus on the joint discovery of novel therapeutic approaches based on findings in human genomics research related to cardiovascular diseases. Bayer (Berlin, Germany) and... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.